Business
ARIUS Presents New Anti-Cancer Antibodies at Major Cancer Conference
ARIUS Presents New Anti-Cancer Antibodies at Major Cancer Conference.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\n\nUpdates and Initial Data on ARIUS Antibodies Disclosed at 97th Annual \nMeeting of the American Association for Cancer Research\n\nTSX Venture Exchange: ARI\n\nTORONTO, March 28 /CNW/ - ARIUS Research Inc. (TSX-VE: ARI) announced\ntoday that it will present a number of new therapeutic anti-cancer antibody\nprograms at the 97th Annual Meeting of the American Association for Cancer\nResearch in Washington, D.C., from April 1-5, 2006. The antibodies were\ngenerated using ARIUS' FunctionFIRST(TM) platform.\nARIUS' FunctionFIRST(TM) platform has been highly effective at\ndiscovering novel antibodies, and targets. These antibodies have been shown to\nbe highly relevant to cancer therapy in proof-of-principle pre-clinical\nexperiments and in some cases are the first of their kind.\n\nAbstract Number: 637, AR53A10.11 and AR58A314.1, 2 ARIUS functional\nmonoclonal antibodies target tumor specific antigens. Sunday, April 2,\n2006 8:00 AM-12:00 PM Section No. 10.\n\nAbstract Number: 3730, Antibodies targeting the tumor-associated antigen\nTROP-2 demonstrate anti-tumor effects in human pancreatic cancer models.\nTuesday, April 4, 2006 8:00 AM-12:00 PM, Section No. 13.\n\nAbstract Number: 4626, Two antibodies directed at complement activation\nregulating protein CD59 exhibit efficacy in multiple human cancer models.\nTuesday, April 4, 2006 1:00 PM-5:00 PM, Section No. 16.\n\nSeparately, ARIUS will provide a scientific update of its anti-cancer\nantibody, ARH460-16-2. This antibody has recently been engineered to be more\nappropriate for human clinical trials. This presentation will discuss some of\nthe properties of the new version of this antibody.\n\nAbstract Number: 639, Chimerized functional anti-CD44 monoclonal\nantibody, ARH460-16-2, is more apogenic and has greater in vivo efficacy.\nSunday, April 2, 2006 8:00 AM-12:00 PM, Section No. 10.\n\nFinally, ARIUS, will discuss some of the key unresolved issues in cancer\nantibody discovery and development. At this presentation, a survey of\nconference attendees will be conducted to solicit a broad spectrum of opinions\nand a draw will be held for a prize for those who participate in the survey.\n\nAbstract Number: 1190, \"If only we had the data....\" Key questions in\noncology antibody development. Sunday, April 2, 2006 1:00 PM-5:00 PM,\nSection No. 12.\n\nAll sessions will be pre...